Mitragynine vs 7-Hydroxymitragynine: A Deep Comparison of Kratom's Two Most Studied Alkaloids

Mitragynine vs 7-Hydroxymitragynine: A Deep Comparison of Kratom’s Two Most Studied Alkaloids

Mitragynine and 7-hydroxymitragynine (7-OH) are the two most studied alkaloids in Mitragyna speciosa. They’re often mentioned together, and both interact with opioid receptors — but they’re not the same compound at different concentrations. The differences are substantial: in structure, potency, natural abundance, mechanism, legal status, and the experience they produce.

Origin and Natural Abundance

Mitragynine is the dominant alkaloid in kratom leaf — typically 50–66% of total alkaloid content. A gram of quality kratom powder contains roughly 15–20mg of mitragynine. It’s the primary active constituent responsible for most of the plant’s pharmacological activity under normal use conditions.

7-Hydroxymitragynine is a minor alkaloid naturally present in trace amounts — typically under 0.02–0.04% of dry leaf weight. A gram of kratom powder contains only 0.2–0.4mg of 7-OH. Its low natural concentration appears to be biologically meaningful, not an accident.

Chemical Structure

Both are Corynanthe-type indole alkaloids sharing a tetracyclic ring system. The critical difference: a hydroxyl group (-OH) at the C-7 position on the 7-OH molecule. This single modification dramatically increases the molecule’s ability to engage the mu-opioid receptor with higher affinity and efficacy.

Potency Comparison

7-OH is dramatically more potent per milligram. In vitro research has estimated 7-OH to be 13–46 times more potent than morphine by weight at the mu-opioid receptor. Mitragynine is significantly less potent — roughly 13 times less potent than morphine in early research.

In natural kratom leaf, you have roughly 50x more mitragynine than 7-OH by weight. Despite lower per-milligram potency, mitragynine dominates because of its numerical abundance. 7-OH, at trace levels, still punches above its weight pharmacologically.

Receptor Pharmacology

Mitragynine is a partial agonist at the mu-opioid receptor with a ceiling effect. It also engages adrenergic receptors (producing stimulating effects) and serotonin receptors — giving it a pharmacological profile genuinely distinct from classical opioids.

7-OH is also a partial agonist at MOR but with substantially higher efficacy and affinity. Its activity is more classically opioid: more pronounced analgesia, sedation, and euphoria, less adrenergic stimulation. Some research suggests a higher potential for opioid-like side effects at elevated doses.

Effect Profile Comparison

Effect	Mitragynine (MIT)	7-Hydroxymitragynine (7-OH)
Low-dose character	Stimulating, alert, focused	Relaxing, mild analgesia
Higher-dose character	Sedating, analgesic, anxiolytic	Strong sedation, analgesia, euphoria
Onset (powder)	20–45 min	15–30 min (extract); 30–60 min (gummy)
Duration	3–5 hours	3–5 hours
Stimulation at low dose	Yes — adrenergic component	Minimal
Tolerance buildup	Gradual	Faster at higher concentrations
Dependency risk	Present; lower than classical opioids	Higher; more classical opioid profile

What Role Each Plays in Whole-Leaf Kratom

In whole-leaf kratom, mitragynine is doing the heavy lifting. Its numerical dominance combined with dual adrenergic and opioid activity creates the characteristic biphasic experience: stimulating at lower doses, transitioning toward sedation and analgesia at higher amounts.

7-OH at trace levels contributes to the overall profile without dominating it. When vendors extract and concentrate 7-OH, they shift the pharmacological center of gravity away from mitragynine-dominant activity toward something much closer to a classical opioid profile — a meaningful change in the nature of the interaction, not just a potency increase.

Legal and Regulatory Differences

7-OH has faced more specific legislative targeting than mitragynine due to its higher potency. States that have scheduled 7-OH specifically include Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin. The regulatory trajectory suggests 7-OH may face increasing scrutiny even in states where kratom itself remains legal. For more detail, see our 7-OH state-by-state legal guide.

Understanding What You’re Buying

When you buy whole-leaf kratom powder, you’re primarily getting mitragynine in a natural-ratio alkaloid matrix. When you buy a kratom extract marketed as containing “7-OH” or “full-spectrum alkaloid enhancement,” you may be getting a product with significantly elevated 7-OH levels — a pharmacologically different product, even if both come from the same plant.

The best way to know what you’re actually getting is a Certificate of Analysis showing actual alkaloid percentages. For a broader look at where both alkaloids sit in the full kratom alkaloid spectrum, our kratom alkaloids potency ranking guide covers MIT, MGM-15, 7-OH, and the minor alkaloids in a single comprehensive reference.

The Bottom Line

Mitragynine is the workhorse of kratom leaf: abundant, moderate in potency, active across both opioid and adrenergic pathways, responsible for the biphasic dose-response that characterizes standard kratom use. 7-OH is the high-potency trace compound: rare in natural leaf, dramatically more potent per milligram, more classically opioid in character, and increasingly the focus of both regulatory attention and product formulation strategies. Understanding this distinction helps you read product labels more critically and make better decisions about what you’re choosing.